Advertisement

Overige verdovende middelen

  • Raymond Niesink

In dit hoofdstuk worden de effecten en het gebruik van enkele middelen beschreven die ingedeeld worden onder de noemer overige verdovende middelen. Deze indeling is niet gebaseerd op grond van de werking van de stoffen, maar op grond van het belangrijkste door de gebruiker gewenste effect. De meeste van de besproken middelen veroorzaken een meestal kortdurende roes. In de voorgaande hoofdstukken is al gebleken dat een bepaalde stof of een bepaald middel meerdere effecten kan hebben, en dat sommige effecten alleen optreden bij bepaalde doseringen of onder bepaalde omstandigheden. De in dit hoofdstuk besproken middelen tellen meestal slechts een kleine groep gebruikers, althans in Nederland, want lijmsnuiven heeft in sommige derde wereldlanden epidemiologische vormen aangenomen. Het percentage gebruikers in de algehele bevolking, of binnen een bepaalde leeftijdsgroep, is voor de meeste middelen zo klein dat deze in algemene bevolkingsonderzoeken niet meetbaar is. Voor sommige van de middelen, zoals GHB en poppers, geldt dat ze wel enige populariteit hebben binnen bepaalde subculturen of binnen bepaalde segmenten van het uitgaanspubliek. Over het algemeen zijn er geen betrouwbare cijfers over het aantal mensen dat dit soort middelen gebruikt, en hoe vaak ze dat doen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Referenties

  1. Balster RL. Neural basis of inhalant abuse. Drug Alcohol Depend 1998; 51: 207–214.PubMedCrossRefGoogle Scholar
  2. Beltman W, Riel AJPH van, Wijnands-Kleukers APG, Vriesman MF, Hengel-Koot IS van den, Vries I de, Meulenbelt J. Smartshops: Overzicht van producten, geclaimde werking en hun medisch-toxicologische relevantie. Bilthoven: RIVM; 1999.Google Scholar
  3. Bielenberg J. Med Monatsschr Pharm 2007; 30: 322–6.Google Scholar
  4. Bland JM, Taylor J. Deaths from accidental drug poisoning in teenagers. Deaths due to volatile substance misuse are greatly underestimated. BMJ 1998 316: 146.PubMedGoogle Scholar
  5. Brattstrom A. Scientific evidence for a fixed extract combination from valerian and hops traditionally used as a sleep-inducing aid. Med Wochenschr 2007 157: 367–370.CrossRefGoogle Scholar
  6. Britt GC, McCance-Katz EF. A brief overview of the clinical pharmacology of “club drugs”. Subst Use Misuse 2005; 40: 1189–1201.PubMedCrossRefGoogle Scholar
  7. Brouette T, Anton R. Clinical review of inhalants. Am J Addict 2001; 10: 79–94.PubMedCrossRefGoogle Scholar
  8. Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol Lett 2004 150: 85–96.PubMedCrossRefGoogle Scholar
  9. CrunelliV, Emri Z, Leresche N. Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 2006; 6: 44–52.PubMedCrossRefGoogle Scholar
  10. Drasbek KR, Christensen J, Jensen K. Gamma-hydroxybutyrate-a drug of abuse. Acta NeurolScand 2006 114: 145–156.Google Scholar
  11. Fromberg E. Kennisbank: CD-rom Psychoactieve stoffen. Den Haag: Stapel & De koning; 2003.Google Scholar
  12. Gahlinger PM. Illegal drugs: a complete guide to their history, chemistry, use and abuse. Sagebrush Press: 203–22.Google Scholar
  13. Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE. Gammahydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997 92: 89–96.PubMedCrossRefGoogle Scholar
  14. Hanson G, Venturelli P. Drugs and society, 6th ed. Ontario: Jones and Bartlett Publishers; 2001.Google Scholar
  15. Haverkos HW, Drotman DP. NIDA technical review: nitrite inhalants. Biomed Pharmacother 1996; 50: 228–230.PubMedCrossRefGoogle Scholar
  16. Huisman M, Brug J, Mackenbach J. Absinthe-is its history relevant for current public health? Int J Epidemiol 2007; 36: 738–744.PubMedCrossRefGoogle Scholar
  17. Korf D, Nabben T, Benschop A. Antenne 2002. Trends in alcohol, tabak en drugs bij jonge Amsterdammers. Amsterdam: Rozenberg Publishers; 2003.Google Scholar
  18. Korf D, Nabben T, Benschop A. Antenne 2005. Trends in alcohol, tabak en drugs bij jonge Amsterdammers. Amsterdam: Rozenberg Publishers; 2006.Google Scholar
  19. Korf D, Nabben T, Leenders F, Benschop A. GHB: tussen extase en narcose. Amsterdam: Rozenberg Publishers; 2002.Google Scholar
  20. Krenz S, Zimmermann G, Kolly S, Zullino DF. Ether: a forgotten addiction. Addiction 2003 98: 1167–1168.PubMedCrossRefGoogle Scholar
  21. Kurtzman TL, Otsuka KN, Wahl RA. Inhalant abuse by adolescents. J Adolesc Health 2001; 28: 170–180.PubMedCrossRefGoogle Scholar
  22. Laborit H, Jouany JM, Gerard J, Fabiani F. Generalities concerning the experimental study and clinical use of sodium gammahydroxybutyrate. Agressologie 1960; 1: 397–406.PubMedGoogle Scholar
  23. Lolin Y. Chronic neurological toxicity associated with exposure to volatile substances. Hum Toxicol 1989; 8: 293–300.PubMedCrossRefGoogle Scholar
  24. Lorenc JD. Inhalant abuse in the pediatric population: a persistent challenge. Curr Opin Pediatr 2003; 15: 204–209.PubMedCrossRefGoogle Scholar
  25. Maisto SA, Galizio M, Connors GJ. Drug use and abuse. Belmont: Thomson Wadsworth; 2004.Google Scholar
  26. Mason PE, Kerns WP. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med 2002; 9: 730–739.PubMedCrossRefGoogle Scholar
  27. Miller PM, Plant M. Drinking, smoking, and illicit drug use among 15 and 16 year olds in the United Kingdom. BMJ 1996: 394–7.Google Scholar
  28. Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001; 10: 232–241.PubMedCrossRefGoogle Scholar
  29. Palmer RB. Gamma-butyrolactone and 1,4-butanediol: abused analogues of gammahydroxybutyrate. Toxicol Rev 2004; 23: 21.PubMedCrossRefGoogle Scholar
  30. Pardi D, Black J. Gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs 2006; 20: 993–1018.PubMedCrossRefGoogle Scholar
  31. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003; CD003383.Google Scholar
  32. Richardson WN, Henderson L. The safety of kava: a regulatory perspective. Br J Clin Pharmacol 2007; 64: 418–420.PubMedCrossRefGoogle Scholar
  33. Ridenour TA, Bray BC, Cottler LB. Reliability of use, abuse, and dependence of four types of inhalants in adolescents and young adults. Drug Alcohol Depend 2007; 91: 40–49.PubMedCrossRefGoogle Scholar
  34. Riegel AC, Zapata A, Shippenberg TS, French ED. The abused inhalant toluene increases dopamine release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. Neuropsychopharmacology 2007; 32: 1558–1569.PubMedCrossRefGoogle Scholar
  35. Romanelli F, Smith KM, Thornton AC, Pomeroy C. Poppers: epidemiology and clinical management of inhaled nitrite abuse. Pharmacotherapy 2004; 24: 69.PubMedCrossRefGoogle Scholar
  36. Saeed SA, Bloch RM, Antonacci DJ. Herbal and dietary supplements for treatment of anxiety disorders. Am Fam Physician 2007; 76: 549–556.PubMedGoogle Scholar
  37. Shepherd RT. Mechanism of sudden death associated with volatile substance abuse. HumToxicol 1989; 8: 287–291.Google Scholar
  38. Stalnikowicz R, Amitai Y, Bentur Y. Aphrodisiac drug-induced hemolysis. J Toxicol Clin Toxicol 2004; 42: 313–316.PubMedCrossRefGoogle Scholar
  39. Williams JF, Storck M. Inhalant abuse. Pediatrics 2007 119: 1009–1017.PubMedCrossRefGoogle Scholar
  40. Wills S. Drugs of abuse. London: The pharmaceutical press; 1997.Google Scholar
  41. Wong CG, Gibson KM, Snead OC. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 2004; 25: 29–34.PubMedCrossRefGoogle Scholar
  42. Wu LT, Pilowsky DJ, Schlenger WE. Inhalant abuse and dependence among adolescents in the United States. J Am Acad Child Adolesc Psychiatry 2004; 43: 1206–1214.PubMedCrossRefGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum 2008

Authors and Affiliations

  • Raymond Niesink

There are no affiliations available

Personalised recommendations